Angiodroid, a Bologna, Italy-based biomedical company focused on developing and marketing an automatic CO2 injector for angiographic imaging, raised €7M in funding.
CDP Venture Capital, by Evolution Fund, led the round alongside ALIAD (Venture Capital fund of the Air Liquide Group), and 8a+ Investment SGR.
The company intends to use the funds to reinforce its international commercial presence, to forge new international partnerships with distributors and MedTech companies, and to support the development of Angiopulse, an IABP console for passive conterpulsation therapy.
Led by Founder and CEO Sebastiano Zannoli, Angiodroid provides an automatic CO2 dosing control system that enables safer angiograms with fewer side effects, offering imaging quality equal to the standard. Its CO2 injector is patented in Europe and US, pending in China and commercialized in more than 55 countries worldwide. Those milestones have been reached in part thanks to international commercial partnerships with primary MedTech companies (i.e. NGC Medical – Medtronic, Siemens Healthcare and Philips), bringing the 2022 company’s turnover to over €3M.
FinSMEs
27/02/2023